Compare CWEN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWEN | TNGX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.1B |
| IPO Year | 2013 | 2020 |
| Metric | CWEN | TNGX |
|---|---|---|
| Price | $28.54 | $21.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $40.36 | ★ $47.00 |
| AVG Volume (30 Days) | 1.4M | ★ 3.6M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 6.27% | N/A |
| EPS Growth | 11.94 | ★ 26.89 |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $1,429,000,000.00 | $62,384,000.00 |
| Revenue This Year | $20.96 | N/A |
| Revenue Next Year | $13.30 | N/A |
| P/E Ratio | $41.03 | ★ N/A |
| Revenue Growth | 4.23 | ★ 48.29 |
| 52 Week Low | $28.57 | $8.30 |
| 52 Week High | $41.74 | $34.39 |
| Indicator | CWEN | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 31.64 | 44.62 |
| Support Level | N/A | $20.49 |
| Resistance Level | $30.98 | $22.01 |
| Average True Range (ATR) | 1.34 | 1.92 |
| MACD | -0.64 | -0.15 |
| Stochastic Oscillator | 0.40 | 18.52 |
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and the owner of modern, sustainable, and long-term contracted assets across North America. The company segments its operations into Flexible Generation, Renewables & Storage, and Corporate divisions. The majority of its revenue is generated from the Renewables & Storage segment.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.